Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
Biological Transport
Female
Follow-Up Studies
Half-Life
Humans
Hypothyroidism
/ complications
Iodine Radioisotopes
/ metabolism
Male
Middle Aged
Radiometry
Radionuclide Imaging
Recombinant Proteins
/ therapeutic use
Retrospective Studies
Thyroid Gland
/ diagnostic imaging
Thyroid Neoplasms
/ complications
Thyrotropin
/ therapeutic use
Tomography, X-Ray Computed
Treatment Outcome
Whole Body Imaging
differentiated thyroid carcinoma
dosimetry
effective half-life
radioiodine therapy
recombinant human thyroid-stimulating hormone
thyroid uptake
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
16
07
2018
accepted:
25
09
2018
pubmed:
14
10
2018
medline:
31
3
2020
entrez:
14
10
2018
Statut:
ppublish
Résumé
Adjuvant radioiodine therapy (RITh) for differentiated thyroid carcinoma is performed either with thyroid hormone withdrawal or with administration of recombinant human thyroid-stimulating hormone (rhTSH). Heterogeneous results have been obtained on the impact of the method of patient preparation on thyroid uptake and whole-body effective half-life. A higher radiation exposure using thyroid hormone withdrawal for several weeks compared with rhTSH was reported in prior studies. It was the aim to examine whether these findings are reproducible in a modern protocol with a short interval between surgery and RITh.
Identifiants
pubmed: 30315143
pii: jnumed.118.217638
doi: 10.2967/jnumed.118.217638
doi:
Substances chimiques
Iodine Radioisotopes
0
Recombinant Proteins
0
Thyrotropin
9002-71-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
631-637Informations de copyright
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.